Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026

Impact · against what's priced in

The positive Phase 2b/3 results for remigromig in diabetic macular edema represent new growth potential for Merck. While the price currently focuses on Keytruda and LIPFENDRA, this first-in-class candidate provides a new path toward the revenue acceleration the market is currently discounting.

MRK+0.20: Not in the price yet
The price assumes

Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026

What matters in this story

How each ticker is affected

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026

What matters in this story

How each ticker is affected

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

Track these names every morning.

Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL

Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026

What matters in this story

How each ticker is affected

Next reads from the same story arc

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026

What matters in this story

How each ticker is affected

Next reads from the same story arc

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

Track these names every morning.

Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL